Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

203.55 -0.32 (-0.16%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
2 Magnificent Dividend Stocks to Buy and Hold Forever
These companies have compelling track records. 
Via The Motley Fool
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive. 
Via MarketBeat
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
Buying these stocks gives you a great chance to beat the benchmark. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock. 
Via Talk Markets
There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors.
This Dividend King is beyond Buffett's reach to fully acquire and is a great pick for income investors. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
Via Benzinga
AbbVie's Options: A Look at What the Big Money is Thinking
Via Benzinga
In-Depth Examination Of 11 Analyst Recommendations For AbbVie
Via Benzinga
AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential
AbbVie is tracking for a new high that may be reached before the end of the year. Acquisitions fuel the growth outlook, cash flow and capital returns. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
Via Benzinga
Biotech Stocks Poised For Another Big Move In Q4
The healthcare sector can be a safe haven if volatility increases. 
Via Talk Markets
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Comparing AbbVie With Industry Competitors In Biotechnology Industry
Via Benzinga
Behind the Scenes of AbbVie's Latest Options Trends
Via Benzinga
(ABBV) - Analyzing AbbVie's Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
3 Magnificent Dividend Stocks to Buy in October
These dividend stocks are great picks as the fall season gets underway. 
Via The Motley Fool
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?
Declining earnings haven't scared billionaire investors away from this stock. 
Via The Motley Fool
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now
These companies can lend growth and dividend returns to a long-term investor's portfolio. 
Via The Motley Fool
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
3 Industries Set To Explode When Interest Rates Drop
Via Talk Markets
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
Blue Shield of California partners with Fresenius Kabi and Evio Pharmacy to cut the cost of Humira's biosimilar to $525 per month, with most members paying $0 out of pocket starting January 2025. 
Via Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026. 
Via Benzinga
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
5 Best Dividend Growth Stocks to Buy in October
These five stocks are known for their generous dividend programs and robust business models. 
Via The Motley Fool
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Meta, Accenture, Disney And A Major Health Care Stock On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Kevin Simpson of Capital Wealth Planning said Meta Platforms is hitting on all cylinders. 
Via Benzinga
15 Best Dividend Stocks for Lifelong Passive Income
These 15 dividend stocks can deliver stable passive income for life. 
Via The Motley Fool
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer option. Analysts project peak sales of up to $5 billion if approved for... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.